Shire snaffles Dyax for $5.9bn plus kicker for HAE drug
Shire, the UK pharmaceutical company, has agreed to acquire US company Dyax for $5.9bn in cash. Deutsche Bank and Morgan Stanley are arranging the financing.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: